Please select the option that best describes you:
Topics:
Genitourinary Cancers • Medical Oncology
Do you treat patients with metastatic renal cell carcinoma who progress on first-line TKI with single agent nivolumab or the combination of nivolumab plus ipilimumab?
Based on new FDA approval of nivolumab plus ipilimumab in the first-line setting for intermediate- and poor-risk disease, would you give the combination for TKI-refractory patients? Would you still consider IMDC risk criteria in this setting?
Answer from: Medical Oncologist at Academic Institution
This is an interesting and timely question that clinicians will face. Although data for nivo monotherapy in the front line is sparse, it is clear to me that the combo has more activity than nivo monotherapy based on ORR and CR rate. It also carries more toxicity. One approach would be to start patie...
Sign in or Register to read more